Fig. 2From: Effect of denosumab switched from bisphosphonates in preventing joint destruction in postmenopausal rheumatoid arthritis patients with anti-cyclic citrullinated peptide antibodiesComparison of the clinical scores at baseline, 12 months, and 24 months. a DAS28-CRP. b VAS. c mHAQ. Results are expressed as the mean and standard deviation. DAS disease activity score, CRP C-reactive protein, VAS visual analogue scale, HAQ Health Assessment QuestionnaireBack to article page